EN2 Regulates Pancreatic Cancer Initiation, Progression, and Epithelial-Mesenchymal Transition Through the Notch...

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• Pancreatic cancer incidence and mortality are rising globally, necessitating research into its molecular drivers.
• Understanding the genetic alterations in pancreatic tumorigenesis is crucial for developing effective treatments.

Purpose of the Study:

• To identify and characterize the novel oncogenic role of Engrailed 2 (EN2) in pancreatic cancer.
• To elucidate the molecular mechanisms underlying EN2's function in pancreatic cancer initiation and progression.

Main Methods:

• Immunohistochemical analysis of pancreatic cancer tissues and cell lines.
• Functional studies including gain- and loss-of-function experiments.
• Analysis of The Cancer Genome Atlas (TCGA) data.
• In vitro and in vivo (xenograft mouse model) experiments using lentiviral-mediated shRNA knockdown of EN2.
• Investigation of Notch signaling pathway involvement.

Main Results:

• Significantly elevated EN2 expression was observed in pancreatic tumor tissues and cell lines compared to normal tissues and cells.
• EN2 upregulation correlated with poor overall survival in pancreatic cancer patients (TCGA data).
• EN2 regulates genes involved in pluripotency, cell survival, cell-cycle progression, drug resistance, and epithelial-mesenchymal transition.
• EN2 knockdown suppressed pancreatic cancer cell proliferation, invasion, and metastasis in vitro and inhibited tumor growth in vivo, partly via Notch signaling inhibition.

Conclusions:

• Engrailed 2 (EN2) is identified as a novel oncogene driving pancreatic cancer initiation, progression, and metastasis.
• EN2 represents a potential therapeutic target for pancreatic cancer, warranting further investigation.